Posttreatment

14,000,000 Leading Edge Experts on the ideXlab platform

Scan Science and Technology

Contact Leading Edge Experts & Companies

Scan Science and Technology

Contact Leading Edge Experts & Companies

The Experts below are selected from a list of 318 Experts worldwide ranked by ideXlab platform

Justus Adamson - One of the best experts on this subject based on the ideXlab platform.

  • inferences about prostate intrafraction motion from pre and Posttreatment volumetric imaging
    International Journal of Radiation Oncology Biology Physics, 2009
    Co-Authors: Justus Adamson
    Abstract:

    Purpose To evaluate the ability of rectal filling, bladder filling, and prostate localization from pre- and Posttreatment volumetric imaging to predict prostate intrafraction motion. Methods and Materials Pre- and Posttreatment cone beam computed tomography images (CBCTs) and intrafractional kV fluoroscopy were acquired at each fraction for 20 prostate patients in supine position, totaling 374 fractions available for analysis. Rectal and bladder filling status were evaluated for each CBCT, and correlation with prostate intrafraction motion measured from kV fluoroscopy was performed. The accuracy of pre and Posttreatment prostate localization to predict intrafraction motion was evaluated. Results Rectal filling status was a significant predictor of prostate intrafraction motion ( p p 0.5 cm 3 within the imaged region (cc = 0.52, p = 0.028). A weak relationship was found between bladder filling and posterior prostate drift for fractions with gas volume ≤0.5 cm 3 (cc = –0.17, p = 0.046). The sensitivity of detecting a 3-, 5-, and 7-mm excursion at MV delivery using Posttreatment imaging was 76%, 75%, and 81% respectively. Conclusions Rectal filling is a significant predictor of prostate intrafraction motion, whereas bladder filling is of limited usefulness. Pre- and Posttreatment localization can provide a reasonable estimate of prostate motion during MV delivery when intrafraction localization is not available, with an error of 95% within 3.1 mm.

  • Inferences About Prostate Intrafraction Motion From Pre- and Posttreatment Volumetric Imaging
    International journal of radiation oncology biology physics, 2009
    Co-Authors: Justus Adamson
    Abstract:

    To evaluate the ability of rectal filling, bladder filling, and prostate localization from pre- and Posttreatment volumetric imaging to predict prostate intrafraction motion. Pre- and Posttreatment cone beam computed tomography images (CBCTs) and intrafractional kV fluoroscopy were acquired at each fraction for 20 prostate patients in supine position, totaling 374 fractions available for analysis. Rectal and bladder filling status were evaluated for each CBCT, and correlation with prostate intrafraction motion measured from kV fluoroscopy was performed. The accuracy of pre and Posttreatment prostate localization to predict intrafraction motion was evaluated. Rectal filling status was a significant predictor of prostate intrafraction motion (p <0.001), and gas volume was correlated with the maximum vector displacement at MV delivery with a correlation coefficient (cc) of 0.37 and p <0.001. Prostate motion was greater for patients who consistently had gas volume >0.5 cm(3) within the imaged region (cc = 0.52, p = 0.028). A weak relationship was found between bladder filling and posterior prostate drift for fractions with gas volume <or=0.5 cm(3) (cc = -0.17, p = 0.046). The sensitivity of detecting a 3-, 5-, and 7-mm excursion at MV delivery using Posttreatment imaging was 76%, 75%, and 81% respectively. Rectal filling is a significant predictor of prostate intrafraction motion, whereas bladder filling is of limited usefulness. Pre- and Posttreatment localization can provide a reasonable estimate of prostate motion during MV delivery when intrafraction localization is not available, with an error of 95% within 3.1 mm.

Alan W. Liesinger - One of the best experts on this subject based on the ideXlab platform.

  • Factors associated with endodontic Posttreatment pain.
    Journal of endodontics, 1993
    Co-Authors: J. Gordon Marshall, Alan W. Liesinger
    Abstract:

    One hundred six patients with pretreatment pain presenting for endodontic treatment participated in a controlled double-blind study of dexamethasone use. Endodontic therapy was performed and, after controlling for use of nonuse of dexamethasone, patient variables and treatment factors were evaluated for their effects on endodontic Posttreatment pain. Patients with no radiographic periapical lesions had significantly more pain than patients with periapical lesions at 8-, 24-, 48-, and 72-h Posttreatment regardless of whether they received placebo or dexamethasone. No other patient or treatment factors correlated with Posttreatment pain. Twenty-two patients in the subgroup receiving placebo reported an 81% incidence of Posttreatment pain, 73% of them required Posttreatment pain medications. By 72-h Posttreatment, the incidence and severity of pain in the placebo group was minimal.

  • Effect of variable doses of dexamethasone on Posttreatment endodontic pain
    Journal of endodontics, 1993
    Co-Authors: Alan W. Liesinger, F. James Marshall, J. Gordon Marshall
    Abstract:

    One hundred six patients with pretreatment pain presenting for endodontic treatment participated in a controlled double blind study. After root canal therapy, the patients were given an intraoral intramuscular injection of either a saline placebo or various dosages of dexamethasone. Posttreatment pain incidence and severity were evaluated at 4, 8, 24, 48, and 72 h. Injection of the various dosages of dexamethasone, taken as a group, was shown to significantly reduce the severity of pain at 4 and 8 h, and 0.07 to 0.09 mg/kg dosage alone significantly reduced pain at 8 h. Patients who received dexamethasone took significantly fewer Posttreatment pain medications than those who received the placebo. Although there was a trend toward a reduction in the incidence of Posttreatment pain for patients who received dexamethasone, the difference was not statistically significant.

J. Gordon Marshall - One of the best experts on this subject based on the ideXlab platform.

  • Factors associated with endodontic Posttreatment pain.
    Journal of endodontics, 1993
    Co-Authors: J. Gordon Marshall, Alan W. Liesinger
    Abstract:

    One hundred six patients with pretreatment pain presenting for endodontic treatment participated in a controlled double-blind study of dexamethasone use. Endodontic therapy was performed and, after controlling for use of nonuse of dexamethasone, patient variables and treatment factors were evaluated for their effects on endodontic Posttreatment pain. Patients with no radiographic periapical lesions had significantly more pain than patients with periapical lesions at 8-, 24-, 48-, and 72-h Posttreatment regardless of whether they received placebo or dexamethasone. No other patient or treatment factors correlated with Posttreatment pain. Twenty-two patients in the subgroup receiving placebo reported an 81% incidence of Posttreatment pain, 73% of them required Posttreatment pain medications. By 72-h Posttreatment, the incidence and severity of pain in the placebo group was minimal.

  • Effect of variable doses of dexamethasone on Posttreatment endodontic pain
    Journal of endodontics, 1993
    Co-Authors: Alan W. Liesinger, F. James Marshall, J. Gordon Marshall
    Abstract:

    One hundred six patients with pretreatment pain presenting for endodontic treatment participated in a controlled double blind study. After root canal therapy, the patients were given an intraoral intramuscular injection of either a saline placebo or various dosages of dexamethasone. Posttreatment pain incidence and severity were evaluated at 4, 8, 24, 48, and 72 h. Injection of the various dosages of dexamethasone, taken as a group, was shown to significantly reduce the severity of pain at 4 and 8 h, and 0.07 to 0.09 mg/kg dosage alone significantly reduced pain at 8 h. Patients who received dexamethasone took significantly fewer Posttreatment pain medications than those who received the placebo. Although there was a trend toward a reduction in the incidence of Posttreatment pain for patients who received dexamethasone, the difference was not statistically significant.

Paul A. Gurbel - One of the best experts on this subject based on the ideXlab platform.

  • The difference between clopidogrel responsiveness and Posttreatment platelet reactivity.
    Thrombosis Research, 2005
    Co-Authors: Waiel M Samara, Udaya S. Tantry, Kevin P Bliden, Paul A. Gurbel
    Abstract:

    Aggregation is the most common measure of platelet reactivity. The relative inhibition of platelet aggregation between pretreatment and Posttreatment is the most common estimate of clopidogrel responsiveness. However, patients responsive to clopidogrel may remain with highly reactive platelets and thus have increased thrombotic risk. Platelet reactivity was determined by ADP-induced aggregation (%) in 62 patients undergoing elective coronary stenting at pretreatment and 5 days postprocedure. All patients were on aspirin (325 mg) and received 300 mg of clopidogrel immediately poststenting and 75 mg qd. Pretreatment reactivity was divided into tertiles. Based on clopidogrel drug responsiveness, nonresponders were defined as <10% relative inhibition of pretreatment aggregation, semiresponders as 10-30%, and responders as >30%. We determined the relation between clopidogrel responsiveness and platelet reactivity. Pretreatment reactivity tertiles by 5 microM ADP were: low (47+/-9%), moderate (64+/-4%), and high (78+/-6%). Eight patients were nonresponders, 18 were semiresponders, and 36 were responders. Clopidogrel responsiveness directly correlated with pretreatment reactivity, 86% of responders had moderate or high pretreatment reactivity, whereas 75% of nonresponders had low pretreatment reactivity. Despite being more responsive, 16% of patients with high pretreatment reactivity and 17% with moderate pretreatment reactivity remained with moderate Posttreatment reactivity. Measuring clopidogrel responsiveness may overestimate the risk of stent thrombosis in nonresponders with low pretreatment reactivity and underestimate risk in those responders who remain with high Posttreatment platelet reactivity. Posttreatment platelet reactivity is a better measure of thrombotic risk than responsiveness to clopidogrel.

  • The difference between clopidogrel responsiveness and Posttreatment platelet reactivity.
    Thrombosis Research, 2004
    Co-Authors: Waiel M Samara, Udaya S. Tantry, Kevin P Bliden, Paul A. Gurbel
    Abstract:

    Abstract Background Aggregation is the most common measure of platelet reactivity. The relative inhibition of platelet aggregation between pretreatment and Posttreatment is the most common estimate of clopidogrel responsiveness. However, patients responsive to clopidogrel may remain with highly reactive platelets and thus have increased thrombotic risk. Methods Platelet reactivity was determined by ADP-induced aggregation (%) in 62 patients undergoing elective coronary stenting at pretreatment and 5 days postprocedure. All patients were on aspirin (325 mg) and received 300 mg of clopidogrel immediately poststenting and 75 mg qd. Pretreatment reactivity was divided into tertiles. Based on clopidogrel drug responsiveness, nonresponders were defined as 30%. We determined the relation between clopidogrel responsiveness and platelet reactivity. Results Pretreatment reactivity tertiles by 5 μM ADP were: low (47±9%), moderate (64±4%), and high (78±6%). Eight patients were nonresponders, 18 were semiresponders, and 36 were responders. Clopidogrel responsiveness directly correlated with pretreatment reactivity, 86% of responders had moderate or high pretreatment reactivity, whereas 75% of nonresponders had low pretreatment reactivity. Despite being more responsive, 16% of patients with high pretreatment reactivity and 17% with moderate pretreatment reactivity remained with moderate Posttreatment reactivity. Conclusion Measuring clopidogrel responsiveness may overestimate the risk of stent thrombosis in nonresponders with low pretreatment reactivity and underestimate risk in those responders who remain with high Posttreatment platelet reactivity. Posttreatment platelet reactivity is a better measure of thrombotic risk than responsiveness to clopidogrel.

Sang Yoon Kim - One of the best experts on this subject based on the ideXlab platform.

  • Risk factors for Posttreatment recurrence in patients with intermediate-risk papillary thyroid carcinoma.
    American journal of surgery, 2020
    Co-Authors: Yong Han Kim, Jong-lyel Roh, Dong Eun Song, Kyung-ja Cho, Seung-ho Choi, Soon Yuhl Nam, Sang Yoon Kim
    Abstract:

    Abstract Background Papillary thyroid carcinoma (PTC) is generally associated with favorable outcomes; however, intermediate-risk requires further evaluation. We therefore examined risk factors for Posttreatment recurrence in patients with intermediate-risk PTC. Methods This study involved 1782 patients who underwent thyroidectomy for intermediate-risk PTC. Univariate and multivariate Cox proportional hazard regression analyses were used to identify the significant factors predictive of Posttreatment recurrence-free survival (RFS). Results Of intermediate-risk factors, univariate analyses showed that clinical and pathological cervical lymph node (LN) positivity (cN1 and pN1), aggressive histology, and multifocality with microscopic extrathyroidal extension were significantly associated with RFS outcomes (all P  5 pN1, and Posttreatment radioactive iodine (RAI)-avid metastatic foci of intermediate risk remained the independent factors predictive of RFS (all P  Conclusion Clinical nodal positivity, the number of positive LNs, and the presence of RAI-avid metastatic foci in the ATA intermediate-risk category might independently decrease RFS in patients with intermediate-risk PTC.